MCA
TXG icon

Maryland Capital Advisors’s 10x Genomics TXG Stock Holding History

Maryland Capital Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-53
Closed -$2K – 254
2022
Q3 		$2K Buy
+53
New +$2.02K ﹤0.01% 229

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Maryland Capital Advisors's TXG Position: Q4 2022 in Review

Maryland Capital Advisors sold out of 10x Genomics (TXG) in Q4 2022, closing a stake of 53 shares — an estimated $2K sold.

Maryland Capital Advisors first reported a position in TXG in Q3 2022 and held it in 1 quarter. The position peaked at $2K in Q3 2022. 268 funds tracked by Wall St. Rank hold TXG as of Q4 2022.

  • Maryland Capital Advisors reported no remaining 10x Genomics position as of Q4 2022 after selling out during the quarter.
  • Maryland Capital Advisors sold 53 10x Genomics shares in Q4 2022, an estimated $2K.
  • Maryland Capital Advisors first reported a position in 10x Genomics in Q3 2022 and held it in 1 quarter.
  • Maryland Capital Advisors's 10x Genomics position peaked at $2K in Q3 2022.
  • 268 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2022.

Based on Maryland Capital Advisors's 13F filing for Q4 2022, filed 18 Jan 2023.